AI Engines For more Details: Perplexity Kagi Labs You
Anxiety Disorders: Pimethixene maleate is occasionally used off-label as an adjunctive treatment for anxiety disorders. Its sedative properties can help alleviate symptoms of anxiety and promote relaxation. However, it is not typically considered a first-line treatment for anxiety disorders due to the availability of other medications with more established efficacy and safety profiles.
Insomnia: Pimethixene maleate's sedative effects make it useful in the management of insomnia, particularly in cases where sleep disturbances are secondary to anxiety or other conditions. It can help induce sleep and improve sleep continuity, leading to better overall sleep quality.
Allergic Reactions: As an antihistamine, pimethixene maleate can be used to alleviate symptoms associated with allergic reactions, such as itching, hives, and allergic rhinitis. Its antihistaminic properties help block the action of histamine, a chemical involved in allergic responses, thereby reducing symptoms of allergy.
Nausea and Vomiting: Pimethixene maleate's antiemetic properties may make it useful in managing nausea and vomiting, particularly in cases where these symptoms are related to motion sickness, vertigo, or medication side effects. Its ability to block certain neurotransmitter receptors in the brain can help alleviate nausea and suppress the vomiting reflex.
Preoperative Anxiety: Pimethixene maleate is sometimes used as a preoperative medication to reduce anxiety and induce sedation in patients undergoing surgical procedures. By promoting relaxation and sedation, it can help alleviate preoperative apprehension and facilitate a smoother induction of anesthesia.
Side Effects: Common side effects associated with pimethixene maleate include drowsiness, sedation, dizziness, blurred vision, dry mouth, constipation, urinary retention, and cognitive impairment. These side effects are typical of medications with sedative and anticholinergic properties and may vary in intensity depending on individual sensitivity and dosage.
Contraindications: Pimethixene maleate is contraindicated in individuals with known hypersensitivity to the drug or its components, as well as in individuals with narrow-angle glaucoma, urinary retention, severe liver impairment, or certain cardiovascular conditions. It should be used with caution in the elderly and in individuals with respiratory conditions such as asthma or chronic obstructive pulmonary disease (COPD).
Drug Interactions: Pimethixene maleate may interact with other medications that have sedative or CNS depressant effects, including alcohol, benzodiazepines, opioids, and certain antidepressants. Concurrent use of these medications may potentiate sedation and increase the risk of adverse effects.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0.3 | -0.3 | |
ADHD | 5.4 | 0.1 | 53 |
Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | 0 |
Allergic Rhinitis (Hay Fever) | 1.2 | 1.6 | -0.33 |
Allergies | 5.1 | 3 | 0.7 |
Allergy to milk products | 1 | 0.9 | 0.11 |
Alopecia (Hair Loss) | 2.2 | 2.2 | |
Alzheimer's disease | 3.3 | 5.3 | -0.61 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 4.4 | 1.2 | 2.67 |
Ankylosing spondylitis | 3.8 | 1.2 | 2.17 |
Anorexia Nervosa | 0.5 | 2.5 | -4 |
Antiphospholipid syndrome (APS) | 1.1 | 1.1 | |
Asthma | 0.7 | 1.9 | -1.71 |
Atherosclerosis | 1.1 | 1.8 | -0.64 |
Atrial fibrillation | 3.6 | 2.1 | 0.71 |
Autism | 8.3 | 10.7 | -0.29 |
Barrett esophagus cancer | 0.4 | 0.4 | |
benign prostatic hyperplasia | 0 | 0 | |
Bipolar Disorder | 1.3 | 1 | 0.3 |
Brain Trauma | 0.8 | 0.7 | 0.14 |
Carcinoma | 3.4 | 3.3 | 0.03 |
Celiac Disease | 2.4 | 4.8 | -1 |
Cerebral Palsy | 1.3 | 1.4 | -0.08 |
Chronic Fatigue Syndrome | 4.1 | 7 | -0.71 |
Chronic Kidney Disease | 1.1 | 1.9 | -0.73 |
Chronic Lyme | 0.7 | -0.7 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.4 | 0.7 | -0.75 |
Chronic Urticaria (Hives) | 0.6 | 2.6 | -3.33 |
Coagulation / Micro clot triggering bacteria | 0.6 | 1 | -0.67 |
Colorectal Cancer | 3.3 | 1.1 | 2 |
Constipation | 2 | 0.7 | 1.86 |
Coronary artery disease | 1.1 | 0.8 | 0.38 |
COVID-19 | 11.9 | 15.2 | -0.28 |
Crohn's Disease | 6.6 | 7.1 | -0.08 |
cystic fibrosis | 0.1 | 1 | -9 |
deep vein thrombosis | 0.1 | 0.5 | -4 |
Depression | 9.6 | 8.2 | 0.17 |
Dermatomyositis | 0.3 | -0.3 | |
Eczema | 0.4 | 1.5 | -2.75 |
Endometriosis | 2.2 | 1.6 | 0.38 |
Eosinophilic Esophagitis | 0.4 | -0.4 | |
Epilepsy | 3.1 | 4 | -0.29 |
Fibromyalgia | 2.7 | 2.8 | -0.04 |
Functional constipation / chronic idiopathic constipation | 5.8 | 3.8 | 0.53 |
gallstone disease (gsd) | 2.1 | 0.5 | 3.2 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.3 | 0.9 | 1.56 |
Generalized anxiety disorder | 0.5 | 1.6 | -2.2 |
giant cell arteritis | 0.2 | -0.2 | |
Graves' disease | 1.7 | 1.4 | 0.21 |
Halitosis | 0.8 | 0.8 | |
Hashimoto's thyroiditis | 2.2 | 0.8 | 1.75 |
Hidradenitis Suppurativa | 0.4 | -0.4 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 3.4 | 0.8 | 3.25 |
hypercholesterolemia (High Cholesterol) | 0.7 | 0.8 | -0.14 |
hyperglycemia | 0 | 3 | 0 |
Hyperlipidemia (High Blood Fats) | 1.2 | 0.4 | 2 |
hypersomnia | 0.5 | -0.5 | |
hypertension (High Blood Pressure | 2.5 | 4.8 | -0.92 |
Hypothyroidism | 0.9 | -0.9 | |
Hypoxia | 1.4 | 1.4 | |
IgA nephropathy (IgAN) | 5.2 | -5.2 | |
Inflammatory Bowel Disease | 2.4 | 9.7 | -3.04 |
Insomnia | 0.9 | 1.2 | -0.33 |
Intelligence | 1.2 | 0.8 | 0.5 |
Intracranial aneurysms | 1.7 | 0.4 | 3.25 |
Irritable Bowel Syndrome | 4.6 | 6.1 | -0.33 |
Liver Cirrhosis | 4 | 2.6 | 0.54 |
Long COVID | 7.5 | 10.1 | -0.35 |
Low bone mineral density | 0.7 | -0.7 | |
Lung Cancer | 0.9 | 1.9 | -1.11 |
ME/CFS with IBS | 0.4 | 2.4 | -5 |
ME/CFS without IBS | 0.6 | 2.7 | -3.5 |
Menopause | 2.2 | 2.2 | |
Metabolic Syndrome | 7 | 9.4 | -0.34 |
Mood Disorders | 12.2 | 8.3 | 0.47 |
multiple chemical sensitivity [MCS] | 0.8 | 0.5 | 0.6 |
Multiple Sclerosis | 4.1 | 6.5 | -0.59 |
Multiple system atrophy (MSA) | 1.7 | 1.1 | 0.55 |
Neuropathy (all types) | 0.9 | 0 | 0 |
neuropsychiatric disorders (PANDAS, PANS) | 0.5 | 0.5 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.2 | 6.3 | -1.86 |
NonCeliac Gluten Sensitivity | 0.3 | -0.3 | |
Obesity | 7.4 | 4.5 | 0.64 |
obsessive-compulsive disorder | 8.1 | 4.1 | 0.98 |
Osteoarthritis | 0.7 | 0.3 | 1.33 |
Osteoporosis | 1.4 | 1.8 | -0.29 |
pancreatic cancer | 0.5 | 0.5 | |
Parkinson's Disease | 2.7 | 3.2 | -0.19 |
Polycystic ovary syndrome | 2.9 | 2.2 | 0.32 |
Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
Premenstrual dysphoric disorder | 1.2 | 0.5 | 1.4 |
primary biliary cholangitis | 0.3 | 1.4 | -3.67 |
Psoriasis | 4.6 | 3.8 | 0.21 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.8 | 3.8 | 0.53 |
Rosacea | 0.6 | 0.4 | 0.5 |
Schizophrenia | 7.5 | 1.5 | 4 |
scoliosis | 1.3 | -1.3 | |
Sjögren syndrome | 3.3 | 4.1 | -0.24 |
Sleep Apnea | 1.1 | 1.2 | -0.09 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.1 | 0.7 | -6 |
Stress / posttraumatic stress disorder | 2.5 | 2.5 | 0 |
Systemic Lupus Erythematosus | 3.4 | 2.3 | 0.48 |
Tic Disorder | 1.8 | 1.9 | -0.06 |
Tourette syndrome | 0.4 | 0.5 | -0.25 |
Type 1 Diabetes | 4.4 | 2.5 | 0.76 |
Type 2 Diabetes | 7.8 | 8.3 | -0.06 |
Ulcerative colitis | 1.8 | 7.1 | -2.94 |
Unhealthy Ageing | 4 | 2.2 | 0.82 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.